HARROW, INC. (HROW) Stock
4 of the hedge funds AlphaScala tracks reported HROW in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $15.69M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 21, 2026.
Which hedge funds own HROW?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 369K | $15.69M | -43% |
| Citadel Ken Griffin | 360K | $15.28M | +63% |
| Millennium Management Israel Englander | 84K | $3.58M | NEW |
| Renaissance Technologies Jim Simons (founder) | 45K | $1.89M | -47% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are HARROW, INC. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 14, 26 | Shojaei Amir | CHIEF SCIENTIFIC OFFICER | SELL | 11.3K | $450K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →HROW price chart
Powered by TradingViewWhat does HARROW, INC. do?
Harrow Inc. is an eyecare pharmaceutical company focused on discovering, developing, and commercializing ophthalmic pharmaceutical products for the U.S. market. The company operates through two primary business segments: The Branded segment, which includes FDA-approved ophthalmology pharmaceutical products such as IHEEZO, IOPIDINE, VEVYE, ZERVIATE, MAXITROL, ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, FLAREX, TRIESENCE, and NATACYN; and The ImprimisRx segment, representing its ophthalmology-focused pharmaceutical compounding business. These products address various eye conditions, including pain and inflammation from cataract surgery, bacterial conjunctivitis, inflammatory conditions, fungal infections, and ophthalmic diseases requiring steroid treatment. Founded in 1998 and headquartered in Nashville, Tennessee, Harrow helps eyecare professionals preserve vision by making prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans through its comprehensive portfolio.